Traders were willing to buoy the market up to Aprilâs record highs on Thursday of last week, but no more. The S&P 500 lost 0.13% of its value on Friday, leaving most market participants wondering if the surprisingly bullish June to date is nothing more than a mirage.
Source: Allan Ajifo via Wikimedia (Modified)
Altria Group (NYSE:MO) was arguably the biggest drag, off 4.5% on doubts that its much-lauded Juul e-cigarette brand would be able to secure the needed approval of the Food and Drug Administration when those products have to get the regulatory agencyâs green lights. Pot stock Canopy Growth (NYSE:CGC) was the bigger disappointment though. It fell more than 8% after investors had a chance to parse the details of Thursday afternoonâs quarterly earnings report. Sales of recreational marijuana fell, sequentially, when theyâre supposed to continue rising on the wake of recent legalization in Canada.
Overstock (NASDAQ:OSTK) did more than its part to keep the market in the black, gaining 15% in response to reports that a couple of potential buyers were mulling the purchase of its e-commerce arm, which is being shed so the company can focus on cryptocurrency.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It just wasnât enough.
Headed into Mondayâs trading, however, itâs the stock charts of AbbVie (NYSE:ABBV), Paychex (NASDAQ:PAYX) and Medtronic (NYSE:MDT) that merit the closest looks. Hereâs why, and what to look for.
In late April it was noted that AbbVie was being squeezed into the tip of a converging wedge pattern, formed by a horizontal support line that had been holding up since October, and a falling resistance line that extended back to last Mayâs high. Although the odds favored a bullish outcome despite the trajectory, it was clear that anything could happen. Waiting on one side or the other to flinch was the key.
Weâre still waiting. Although ABBV shares slipped below that key floor a couple of times in the meantime, the floor mostly remains intact. Some new falling resistance lines have since come into play, though the old one marked with a dashed blue line remains part of the equation. Either way, weâre getting closer to a decision, if only because thereâs not much room left to meander between support and resistance.
Click to Enlarge
Back in March we looked at Medtronic as it was toying with the idea of a major break above a resistance line around $94, plotted in blue on the daily chart. That didnât happen ⦠at least not right away. As it turns out, MDT would have to peel back one more time and then try again. This monthâs effort did the job.
The speed and distance of that move, however, has also spurred concerns that this usually volatile name is already due for some profit-taking again. When one takes a step back and looks at the longer-term view, however, itâs clear thereâs room for a bit more upside until the upper boundary of a major trading range is encountered again.
Click to Enlarge
Finally, with nothing more than a quick glance at the Paychex chart, it appears the stock is still in an uptrend, though a slowing one. And, perhaps that benign outcome is what lies ahead. Only time will tell.
But, given the sheer scope of the rally since late last year, the slowdown is concerning simply because it may point to an outright reversal into a downtrend. The pump for such a pullback is certainly primed. The good news is, we know exactly where the make-or-break lines are, and what they are.
Click to Enlarge
As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley.
Compare Brokers
The post 3 Big Stock Charts for Monday: Medtronic, Paychex and AbbVie appeared first on InvestorPlace.